Gefitinib Enhances Mitochondrial Biological Functions in NSCLCs with EGFR Mutations at a High Cell Density.
Sign Up to like & getrecommendations! Published in 2017 at "Anticancer research"
DOI: 10.21873/anticanres.11884
Abstract: BACKGROUND/AIM Gefitinib is a tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and has been approved for the treatment of non-small cell lung cancers (NSCLCs) with EGFR mutations. Here we demonstrated that gefitinib induced… read more here.
Keywords: nsclcs egfr; cell density; gefitinib; high cell ... See more keywords